Association between 318C/T polymorphism of the CTLA-4 gene and systemic lupus erythematosus in Iranian patients by Shojaa, M. et al.
ORIGINAL ARTICLE
Association between 318C/T polymorphism of the CTLA-4
gene and systemic lupus erythematosus in Iranian patients
Mahdieh SHOJAA,1,2 Mehrdad AGHAIE,3 Mahsa AMOLI,4 Naemeh JAVID,1
Fatemeh SHAKERI,1 Patricia KHASHAYAR,2 Alijan TABARRAEI,1 Abbas A. KESHTKAR,2
Hamid R. JOSHAGHANI,1 Arghavan KOUROSHNIA,4 Mostafa QORBANI,5,6 Faranak
MAHMOUDI,7 Ramin MOHEBBI8 and Neda RANJBARPOUR7
1Golestan University of Medical Sciences, Gorgan, 2Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences
Institute, Tehran University of Medical Sciences, Tehran, 3Department of Rheumatology, Faculty of Medicine, Bone Joint and
Connective Tissue Research Center (BJCRC), Golestan University of Medical Sciences, Gorgan, 4Endocrinology & Metabolism
Research Center (EMRC), Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran,
5Department of Public Health, Alborz University of Medical Sciences, Karaj, 6Non-communicable Diseases Research Center,
Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, 7Genetics Department,
Islamic Azad University Tehran, Tehran Medical Branch, and 8Medical School, Shahed University of Medical Sciences, Tehran,
Iran
Abstract
Background: Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an important negative regulator of T-cell
response. It is a functional candidate gene connected with susceptibility to systemic lupus erythematosus (SLE).
We analyzed the role of 318C/T polymorphism in the promoter region of the CTLA-4 gene in Iranian patients
suffering from SLE.
Methods: A total of 180 SLE patients and 304 healthy ethnically matched controls were enrolled in the study.
DNA was extracted from blood samples according to the standard procedure. Polymerase chain reaction restric-
tion fragments length polymorphism (PCR-RFLP) was used to analyze the genotype and allele frequencies of
these polymorphisms.
Results: The CC genotype was observed in 170 (94.5%) of the SLE patients, which was significantly different
compared to the controls (251 [82.4%]; P = 0.0001, OR = 3.51 95%CI = 1.77–7.53). T allele was significantly
more common in the controls (9.2%) compared to SLE patients 2.8% (P = 0.0001, OR = 0.26, 95%CI = 0.13–
0.53). There was no significant correlation between different genotypes and age, gender or family history of SLE
in the studied population.
Conclusion: It can be concluded that 318C/T polymorphism of CTLA-4 gene might play a significant role in
the development of SLE in the Iranian patients.
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BACKGROUND
Systemic lupus erythematosus (SLE) is an autoim-
mune multisystem disorder characterized by the
production of multiple immunoglobulin G (IgG) au-
toantibodies.1 The disease can affect multiple tissues
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and organs, including kidneys, joints, skin, pleura and
pericardium, diverse blood cells and the nervous sys-
tem.2 It is more frequently reported in individuals in
the second, third or fourth decades of life.3 SLE
afflicts more than 1 million individuals in the US
and 3.2–14.1 cases per 100 000 women of European
descent.4,5 The disease is reported in 40 per 100 000
of the Iranian population.6 The etiology and patho-
genesis of SLE still remains unknown; however
genetic predisposition and environmental factors are
deemed to play an important role in its pathogene-
sis.7 Twin and family studies have provided evidence
for the involvement of genetic factors in this disease,
showing an increased concordance among monozy-
gotic twins compared with the dizygotic ones and a
high degree of familial clustering for the disease.8
Cytotoxic lymphocyte antigen-4 (CTLA-4) plays an
important role in regulating T cell activation, helping
to limit T cell response in inflammatory conditions. It
may also play a role in maintaining peripheral toler-
ance.9 Similar to Graves’, celiac, autoimmune thyroid
disease, type I diabetes, rheumatoid arthritis and mul-
tiple sclerosis, the expression of CTLA-4 is increased
in patients with active SLE and thus the gene is
believed to have a key role in the pathogenesis of the
disease.10,11 One of them is located at the 318 posi-
tion in the promoter region. Using a case–control
study, we determined the role of 318C/T polymor-
phism in SLE pathogenesis.
MATERIALS AND METHODS
Patients
One hundred and eighty SLE patients (15 male and 165
female) with a mean age of 32.99  10.45 years (range
13–70 years) were enrolled in the study. Three hundred
and four ethnically and age-matched healthy controls
(23 male and 281 female) with no history of autoim-
mune diseases were recruited from the Azar 5th Teach-
ing Hospital affiliated to Gorgan University of Medical
Sciences, Gorgan, Iran. All the SLE patients fulfilled the
American College of Rheumatology 1997 revised crite-
ria for SLE.12 The study was approved by the local ethics
committee and a written informed consent was
obtained from each patient.
DNA extraction and genotyping
The DNA was extracted from peripheral blood lympho-
cytes using a DNA extraction kit (Roche Applied Sci-
ence, Penzberg, Germany) according to the standard
protocol from the manufacturer. Polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) was used to analyze the 318C/T polymor-
phism in the promoter region. PCR was carried out
using the following primers: forward 5′-AAATGAATTG
GACTGGATGGT-3′ and reverse 5′-TTACGAGAAAG
GAAGCCGTG-3′. Amplification was carried out after
initial denaturation at 94°C (2 min), followed by 30
cycles at 94°C (30 s), 60°C (30 s), 72°C (30 s) and a
final extension at 72°C (7 min). The PCR products were
digested using restriction enzyme MseI (New England
BioLabs, Hitchin, UK) at 37°C for 3 h and then were
analyzed on 3% agarose gel using ethidium bromide
staining. The amplified DNA consisted of 226 and
21 bp fragments (C allele) or 21, 96 and 130 bp frag-
ments (T allele; Fig. 1).
Statistical analysis
The frequency of alleles and genotypes were assessed
using direct counting. Chi-square and Fisher’s exact test
were used to compare the association between the
alleles and genotype frequencies and SLE. P-val-
ues < 0.05 were considered statistically significant. The
strength of the association between the incidence of
SLE and the frequency of the studied alleles or geno-
types of polymorphism was estimated using odds ratios
(OR) and 95% confidence intervals (CI). Statistical
analysis was conducted with STATA V.8 software (Stata-
Corp., College Station, TX, USA).
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Figure 1 Genotyping of the CTLA-4 gene promoter 318
C/T polymorphism bu MseI restriction fragment length poly-
morphism. DNA size marker (100 bp ladder). (1) TT geno-
type (21, 96, 130 bp); (2) CT genotype (21, 96, 130, 226 bp);
(3) CC genotype (226, 21 bp). The 21 fragments are not visi-
ble on the agarose gel.
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RESULTS
Approximately 86.2% of the studied patients were
aged between 15 and 45 years; 91.7% of them were
female and 15% had a positive family history of SLE.
Table 1 shows the frequency of different genotypes
and alleles for the 318C/T polymorphism in the
studied group. The CC genotype was observed in
94.5% of the SLE patients and 82.4% of the controls;
the difference was statistically significant (odds ration
[OR] = 3.51; P = 0.0001). The distribution of the
genotype in the control group was in Hardy–Weinberg
equilibrium.
The CT genotype, on the other hand, was more fre-
quently observed in the control group (17.1% vs. 5.5%,
P = 0.0001; OR = 0.28). The T allele was also signifi-
cantly more frequent among the controls (9.2% vs.
2.8% in SLE patients; P = 0.0001; OR = 0.26).
Although the C allele was more common in the
patients, we found no significant difference in the fre-
quency of the C allele between the patients and the con-
trols (P = 0.62). We could not find any significant
correlation between the individual ages, gender, family
history of SLE and different genotypes (Table 2).
DISCUSSION
Genetics is an important risk factor for SLE. This comes
while many studies have reported that different envi-
ronmental factors act together to place genetically pre-
disposed individuals at a higher risk of developing
SLE.13 In the present study, we determined a strong
association between the CTLA-4 polymorphism and
susceptibility to SLE in the Iranian population. Our
results showed a significant association between CC
genotype and SLE, adding that CT genotype and T allele
are more common in the healthy population.
Contrary to our findings, Lee et al.14 reported that CT
genotype was more common in SLE patients, adding
that CC and TT genotypes were more frequently seen in
their controls. However, the difference noted between
our results could be explained by race diversity between
the Iranian and Korean populations. Although this
study indicates a different pattern, it is the only study to
our knowledge that is in line with our findings, to show
a positive correlation between 318 polymorphism
and SLE.15–21
With respect to the CTLA-4 gene, no association was
found between the presence of CTLA-4 and SLE in indi-
viduals from the US,15 Malaysia,16 Korea,17 England,18
Japan19 and Spain.20 Although the results of the study
conducted by Lee et al.14 differed from that of Hudson
et al.,17 which involved the same population (Korean),
these discrepancies may arise from various features,
including gender, sample size and age at the onset of
disease. The results indicate that CTLA-4 gene polymor-
phism is linked with SLE, whereas the majority of the
studies have reported a negative association between
318C/T polymorphism and SLE.15–21
The inconsistent results of the present study may be
partially explained by the differences in the ethnicities
of the studied population. SLE, as a systemic autoim-
mune disease, is highly heterogenenous with regard to
severity, organ involvement and autoantibody profile.
Autoantibodies against a variety of autoantigens are
known to be associated with organ involvement associ-
ated with the disease. Therefore, we investigated clinical
futures of SLE.
Other polymorphisms in CTLA4 gene, including
1722 T/C, 1661 A/G and +49 A/G are shown to be
associated with multiple sclerosis as an autoimmune
condition in the Iranian population.22 Therefore it
Table 1 Association between CTLA-4 318C/T allele and SLE
risk factors
Risk factor C (%) T (%) Total (%) P-value
Age (years)
< 15 8 (2) 0 (0) 8 (2) 0.42
15–45 300 (83.3) 10 (3) 310 (86.3)
More than 45 42 (11.7) 0 (0) 42 (11.7)
Gender
Female 321 (89.2) 9 (2.5) 330 (91.7) 0.59
Male 29 (8) 1 (0.3) 30 (8.3)
Family history of SLE
Yes 53 (14.7) 1 (0.3) 54 (15) 0.54
No 297 (82.5) 9 (2.5) 306 (85)
SLE, systemic lupus erythematosus.
Table 2 Genotypic distribution and allelic frequencies of
CTLA-4 318C/T polymorphisms in the Iranian SLE patients
and healthy controls
Exon 1 SLE (%)
N = 180
Control (%)
N = 304
P-value OR (95%CI)
Genotype
CC 170 (94.5) 249 (81.9) 0.0001* 3.75
(1.86–7.57)
Allele
C 350 (97.2) 552 (90.8) 0.0001 0.26
(0.13–0.53)T 10 (2.8) 56 (9.2)
*CC versus TT + CT.
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could be hypothesized that the association of 318 CC
genotype with SLE found in this study might be second-
ary to the disequilibrium with these single nucleotide
polymorphisms (SNPs). Therefore, it will be interesting
to examine the association between these SNPs individ-
ually and as haplotypes in our patients in the future.
Our study did not report any link between age, gen-
der and having a positive family history of SLE and
318C/T genotypes. This comes while previous studies
had reported CTLA-4 318C/T polymorphisms in SLE
patients.15–21 This is the first report of association
between 318 CT polymorphism and clinical features
of SLE and the first to show an association between
318CT and SLE among our population.
Studying the expression of CTLA4 in tissue and blood
samples obtained from subjects with different geno-
types can shed light on the mechanism of CTLA4
involvement in vulnerability to developing SLE. Previ-
ous studies have shown the functional effect of 318C/
T polymorphism on the promoter activity of CTLA423
with the T allele corresponding to a significantly higher
promoter activity compared to the C allele. Other stud-
ies have also demonstrated increased expression of
CTLA-4 after stimulating the cell surface and at the mes-
senger RNA level in non-stimulated cells in individuals
carrying the T allele of this polymorphism.24
In conclusion, the 318C/T polymorphism appears
to play a significant role in the development of SLE in
the Iranian population. Therefore, further studies on
populations, especially from other Middle Eastern
countries, are needed to confirm our results.
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